MYC and prostate cancer: To address this unmet need, we conducted a genome-wide CRISPR knockout (KO) screen in two biological replicates using murine MycCaP prostate cancer cells and the well-characterized small-molecule MYC inhibitor MYCi975 (Fig. 1A).